User login
With the approvals of three new therapies for multiple myeloma in just the last month – elotuzumab, ixazomib, and daratumumab – sessions at ASH 2015 will be buzzing with discussions of how the availability of these new therapies is likely to influence disease management. Other leading abstracts, highlighted at a press conference prior to the annual meeting of the American Society of Hematology, address gene therapy, precision medicine, and stem cell transplant for sickle cell disease. We’re providing the links to these top abstracts here, and invite you to look for our upcoming daily newsletters and next-best-thing-to-being-there coverage of ASH.
Experimental, targeted treatments for blood cancer
• 507: Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase I/II Study (GEN503).
• 727: Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase III Tourmaline-MM1 Study (NCT01564537).
• 391: Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial).
• 495: Results from the International, Randomized Phase III Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM).
Experimental gene therapy
• 201: Update of Results from the Northstar Study (HGB-204): A Phase I/II Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product).
• 261: Lentiviral Hematopoietic Stem Cell Gene Therapy for Older Patients with X-Linked Severe Combined Immunodeficiency.
Precision medicine
• 250: Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia.
• Special Scientific Symposium: Precision Medicine in Cancer Therapy.
Coagulation
• 5: Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study.
New sickle cell disease research
•541: Hematopoietic Stem Cell Transplantation from HLA Identical Sibling For Sickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR.
With the approvals of three new therapies for multiple myeloma in just the last month – elotuzumab, ixazomib, and daratumumab – sessions at ASH 2015 will be buzzing with discussions of how the availability of these new therapies is likely to influence disease management. Other leading abstracts, highlighted at a press conference prior to the annual meeting of the American Society of Hematology, address gene therapy, precision medicine, and stem cell transplant for sickle cell disease. We’re providing the links to these top abstracts here, and invite you to look for our upcoming daily newsletters and next-best-thing-to-being-there coverage of ASH.
Experimental, targeted treatments for blood cancer
• 507: Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase I/II Study (GEN503).
• 727: Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase III Tourmaline-MM1 Study (NCT01564537).
• 391: Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial).
• 495: Results from the International, Randomized Phase III Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM).
Experimental gene therapy
• 201: Update of Results from the Northstar Study (HGB-204): A Phase I/II Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product).
• 261: Lentiviral Hematopoietic Stem Cell Gene Therapy for Older Patients with X-Linked Severe Combined Immunodeficiency.
Precision medicine
• 250: Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia.
• Special Scientific Symposium: Precision Medicine in Cancer Therapy.
Coagulation
• 5: Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study.
New sickle cell disease research
•541: Hematopoietic Stem Cell Transplantation from HLA Identical Sibling For Sickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR.
With the approvals of three new therapies for multiple myeloma in just the last month – elotuzumab, ixazomib, and daratumumab – sessions at ASH 2015 will be buzzing with discussions of how the availability of these new therapies is likely to influence disease management. Other leading abstracts, highlighted at a press conference prior to the annual meeting of the American Society of Hematology, address gene therapy, precision medicine, and stem cell transplant for sickle cell disease. We’re providing the links to these top abstracts here, and invite you to look for our upcoming daily newsletters and next-best-thing-to-being-there coverage of ASH.
Experimental, targeted treatments for blood cancer
• 507: Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase I/II Study (GEN503).
• 727: Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase III Tourmaline-MM1 Study (NCT01564537).
• 391: Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial).
• 495: Results from the International, Randomized Phase III Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM).
Experimental gene therapy
• 201: Update of Results from the Northstar Study (HGB-204): A Phase I/II Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product).
• 261: Lentiviral Hematopoietic Stem Cell Gene Therapy for Older Patients with X-Linked Severe Combined Immunodeficiency.
Precision medicine
• 250: Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia.
• Special Scientific Symposium: Precision Medicine in Cancer Therapy.
Coagulation
• 5: Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study.
New sickle cell disease research
•541: Hematopoietic Stem Cell Transplantation from HLA Identical Sibling For Sickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR.
FROM ASH 2015
